Cleveland Clinic and IBM Unveil Landmark 10-Year Partnership to Accelerate Discovery in Healthcare and Life Sciences
IBM Hybrid Cloud, High Performance Computing, Artificial Intelligence, and Quantum Computing technologies will serve as the foundation for Cleveland Clinic’s newly launched Global Center for Pathogen Research & Human Health.
NIH Awards $4.6M to Study Human Cytomegalovirus Latency and Reactivation
Dr. O’Connor’s team will investigate the underlying mechanisms by which human cytomegalovirus manipulates host cells to regulate viral latency and reactivation.
New Study From Cleveland Clinic Pathogens Researchers Points to Novel Drug Target for Treating COVID-19
Dr. Gack and other FRIC researchers discovered that a coronavirus enzyme blocks the activity of a previously undefined host immune response, suggesting therapeutics that inhibit the enzyme may help treat COVID-19.
Nanoparticle-delivered COVID-19 Vaccine Candidate Shows Promise in Preclinical Studies
Dr. Jung and his team have developed a vaccine candidate that targets the primary binding site between SARS-Cov-2 and human cells, which universally produced neutralizing antibodies and prevented infection in preclinical models.
Characterizing Patient Immune Responses to Emerging Tick-borne Virus
Using patient samples, Dr. Jung and his team uncovered inflammatory biomarkers associated with severe disease and death caused by SFTSV infection, and identified the critical role B cells play in infection.
Study Reveals Cause of Common Zika Virus Birth Defect
Dr. Jung and his team defined the molecular mechanisms that underlie fetal brain calcification caused by Zika virus infection, most notably identifying the role of the protease NS3 in driving the virus-induced abnormal brain development.
Cleveland Clinic Announces New Global Center for Pathogen Research & Human Health
Through a $500 million partnership with the State of Ohio, JobsOhio and Ohio Development Services Agency, Cleveland Clinic will strengthen and grow its commitment to infectious disease research as the new Center will support research, education and grow new jobs in Ohio.
Latest COVID-19-Related Prediction Model from Cleveland Clinic Forecasts Risk for ICU Admission, Death
This latest prediction model from Drs. Kattan and Jehi helps identify which COVID-19-positive patients are at greatest risk for severe COVID-19, which may help physicians prioritize who should receive COVID-19 vaccines first.
COVID-19 May Also Invade the Central Nervous System, Cause Neurological Illnesses
In a new review, Dr. Ghosh notes that recent case reports of COVID-19-associated neurological disorders, which may result from blood-brain barrier dysfunction, demonstrate the virus’ neuroinvasive potential.
Cleveland Clinic Researchers Use “Big Data” Approach to Identify Melatonin as Possible COVID-19 Treatment
Dr. Cheng and colleagues developed a network medicine strategy to predict disease manifestations associated with COVID-19 and find existing drugs with the potential to be effective COVID-19 treatments.
COVID-19 Risk Model Developed by Cleveland Clinic Now Available to Health Systems Around the World Through Epic
Healthcare organizations can present the clinically validated model—first published by Drs. Kattan and Jehi in a June edition of CHEST—to patients in MyChart to assess their risk of having COVID-19.
Cleveland Clinic Study Finds No Association Between Influenza Vaccine and COVID-19 Risk
Using patient data from Cleveland Clinic’s COVID-19 registry, Dr. Zein found that receiving the flu vaccine does not increase risk for COVID-19 or worsen associated disease outcomes, suggesting it is safe and advisable to receive the influenza vaccine this flu season.
New Prediction Model Can Forecast Personalized Risk for COVID-19-Related Hospitalization
Drs. Jehi and Kattan have developed their second COVID-19 nomogram—this latest one helping physicians to anticipate which COVID-19 patients are most likely to be admitted to the hospital for related symptoms and complications.
Cleveland Clinic Names Chair of Department of Cancer Biology
Jae Jung, PhD, a renowned expert in virus-induced cancers and immunology research, will lead Lerner Research Institute’s Department of Cancer Biology and will also serve as director of Cleveland Clinic’s Center for Global and Emerging Pathogens Research.
$2.8M Grant Awarded to Develop Vaccine to Counter Emerging Tick-Borne Virus
The funds, the first to go to Cleveland Clinic’s new Center for Global and Emerging Pathogens, will support Dr. Jung’s work to test four vaccine candidates against the virus that causes severe fever with thrombocytopenia.
Genetic Factors May Influence COVID-19 Susceptibility
Dr. Cheng's team found a possible association between ACE2 and TMPRSS2 polymorphisms and COVID-19 susceptibility.
Cleveland Clinic Florida Opens Florida Research and Innovation Center
The new center, which will complement and expand research underway at Lerner Research Institute, will focus on research related to cancer and infectious diseases, including COVID-19 and immune system response.
Researchers Develop First Model to Predict Likelihood of Testing Positive for COVID-19 and Disease-Related Outcomes
The first-in-class individual prediction model, developed by Drs. Jehi and Kattan, reveals new characteristics that affect a person's risk for testing positive, including taking certain medications and vaccination history.
Cleveland Clinic Names Director of Center for Immunotherapy and Precision Immuno-Oncology
Timothy Chan, MD, PhD, a renowned cancer researcher and a pioneer in using genomics to determine patients’ response to immunotherapies, will lead the newly created center, which exists at the intersection of cancer research, therapeutics and care.
Researchers Develop COVID-19 Case & Mortality Dashboard
Staff in the Department of Quantitative Health Sciences have created a dashboard to help stay current on COVID-19 case and mortality U.S. data.
Network-Based Drug Discovery for the Emerging COVID-19 Epidemic
By harnessing the powers of systems pharmacology and predictive modeling, Dr. Cheng identified 16 drugs and three drug combinations that may be candidates for repurposing as potential COVID-19 treatments.
New Chair Named for Department of Inflammation & Immunity